Journal for ImmunoTherapy of Cancer · 2020 · 62 citations · 16 references
MedicineImmunologyOncologyGlial BiologyTumor HeterogeneityTumor ImmunologyBrain TumorsImmune Cell InfiltrationImmune HeterogeneityPediatric Brain TumorsT Cell BiologyTumor-infiltrating LymphocytesGlioma GradingImmune Cell DensityImmunofluorescence AssaysIntratumoral Immune HeterogeneityMass CytometryPediatric Low-grade GliomaStem Cell Marker ExpressionTissue-resident Memory T Cells
Brain tumors are the leading cause of cancer-related mortality in children and have distinct genomic and molecular features compared with adult glioma. However, the properties of immune cells in these tumors has been vastly understudied compared with their adult counterparts. We combined multiplex immunofluorescence immunohistochemistry coupled with machine learning and single-cell mass cytometry to evaluate T-cells infiltrating pediatric glial tumors. We show that low-grade tumors are characterized by greater T-cell density compared with high-grade glioma (HGG). However, even among low-grade tumors, T-cell infiltration can be highly variable and subtype-dependent, with greater T-cell density in pleomorphic xanthoastrocytoma and ganglioglioma. CD3+ T-cell infiltration correlates inversely with the expression of SOX2, an embryonal stem cell marker commonly expressed by glial tumors. T-cells within both HGG and low-grade glioma (LGG) exhibit phenotypic heterogeneity and tissue-resident memory T-cells consist of distinct subsets of CD103+ and TCF1+ cells that exhibit distinct spatial localization patterns. TCF1+ T-cells are located closer to the vessels while CD103+ resident T-cells reside within the tumor further away from the vasculature. Recurrent tumors are characterized by a decline in CD103+ tumor-infiltrating T-cells. BRAF V600E mutation is immunogenic in children with LGG and may serve as a target for immune therapy. These data provide several novel insights into the subtype-dependent and grade-dependent changes in immune architecture in pediatric gliomas and suggest that harnessing tumor-resident T-cells may be essential to improve immune control in glioma.
16
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Moshe Sade-Feldman, Keren Yizhak, Stacey L. Bjorgaard et al. · Cell · 2018 · 2K citations · Full text
Life Sciences, Immunology, Oncology +14
Cancerous stem cells can arise from pediatric brain tumors
Houman D. Hemmati, Ichiro Nakano, Jorge A. Lazareff et al. · Proceedings of the National Academy of Sciences · 2003 · 1.8K citations · Full text
Medicine, Cell Biology, Oncology +15
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Hubing Shi, Willy Hugo, Xiangju Kong et al. · Cancer Discovery · 2013 · 986 citations · Full text